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Synergistic Signaling from 
Extracellular Matrix–Growth Factor 
Complexes
Richard	A.F.	Clark1
Investigations on extracellular matrix (ECM) and growth factor (GF) complexes 
have revealed an underappreciated phenomenon: they can either negate GF 
activity or generate synergistic signals for cell function, in particular mitogen-
esis. ECM and pericellular matrix molecules were first recognized to complex 
with GFs and regulate GF activity by the seminal observations that basic fibro-
blast growth factor (bFGF or FGF-2) required binding to a cell-surface heparin 
sulfate proteoglycan and to its authentic cell-surface receptor for biological 
activity (Klagsbrun and Baird, 1991; Yayon et al., 1991). Subsequently, numer-
ous ECM–GF interactions that modulate GF activity were discovered; we have 
reviewed many of these findings (Macri et al., 2007).
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In	this	issue,	Upton	et al.	(2008)	demon-
strate	 that	 vitronectin	 (VN)	 complexes	
with	insulin-like	growth	factor	(IGF)	and	
IGF-binding	 proteins	 (IGFBPs)	 could	
enhance	migration	of	human	keratino-
cytes	in vitro	and	possibly	in vivo.	Given	
that	some	ECM–GF	complexes,	includ-
ing	VN–IGF–IGFBP,	markedly	 enhance	
GF	activity,	such	complexes	might	drive	
down	the	GF	dose	required	for	wound	
therapy	 to	 the	nanogram	 level.	 Such	a	
low	GF	dose—hundreds-	to	thousands-
fold	 less	 than	 that	 currently	 needed—
would	 potentially	 provide	 great	 mon-
etary	savings	for	wound	treatments	with	
GF	 products.	 Furthermore,	 the	 same	
investigators	 previously	 demonstrated	
that	 VN	 could	 form	 complexes	 with	
GFs	other	 than	 IGF,	such	as	epidermal	
growth	 factor	 (EGF).	 ECM	 molecules	
capable	 of	 binding	 a	 menu	 of	 GFs	
might	 provide	 breakthrough	 technol-
ogy	for	wound	treatment	because	such	
molecules	might	 localize	 endogenous-
ly	 produced	GFs	 to	 injured	 tissue	 and	
thereby	 solve	 the	 dilemma	 of	 which	
specific	array	of	GFs	should	be	added	to	
wounds	to	promote	healing.
We	 previously	 reported	 that	 the	
ECM	 proteins	 fibronectin	 (FN)	 and	
fibrin	 accumulate	 in	 injured	 tissue	 as	
provisional	matrix	molecules	 (Clark et 
al.,	 1982).	 VN,	 osteonectin	 (SPARC),	
thrombospondin	(TSP),	and	tenascin,	as	
well	as	FN	and	fibrin,	are	now	known	
to	 fit	 this	 category.	 Interestingly,	 all	
these	 ECM	 proteins	 have	 been	 dem-
onstrated	 to	bind	GFs	and	 to	enhance	
their	activity,	except	for	SPARC,	which	
binds	 platelet-derived	 growth	 fac-
tor	 (PDGF)	 and	 vascular	 endothelial	
cell	 growth	 factor	 (VEGF)	 but	 inhibits	
their	GF	activities	 (Macri et al.,	2007).	
Complexities	 arise	 with	 TSP	 because	
it	 either	 activates	 or	 inhibits	 GFs.	 For	
example,	TSP-1	 activates	 transforming	
growth	 factor-β	 (TGF-β)	 (Young	 and	
Murphy-Ullrich,	 2004)	 but	 inhibits	
VEGF	 (Greenaway et al.,	 2007).	 From	
these	data	 it	can	be	hypothesized	 that	
provisional	 matrix	 proteins	 bind	 and	
regulate	GFs	 in	 injured	 tissue.	 In	 fact,	
one	of	 the	major	 problems	 in	 chronic	
wounds	 may	 be	 the	 absence	 of	 pro-
visional	 matrix	 proteins,	 such	 as	 FN	
and	perhaps	VN	(Herrick et al.,	1992),	
secondary	 to	 their	 degradation	 by	 the	
plethora	of	proteolytic	enzymes	present	
(Grinnell	and	Zhu,	1994,	1996).
Results	 from	 provisional	 matrix	
protein	 null	 mice	 support	 such	 a	
hypothesis,	 at	 least	 in	 part.	 For	 exam-
ple,	 SPARC-null	 mice	 demonstrate	
enhanced	 cutaneous	 wound	 healing	
(Bradshaw et al.,	 2002);	 in	 contrast,	
VN-null	 mice	 demonstrated	 impaired	
angiogenesis	during	cutaneous	wound	
repair	(Jang et al.,	2000).	Mice	overex-
pressing	TSP	have	delayed	wound	heal-
ing	and	diminished	angiogenesis	(Streit 
et al.,	2000).	A	caveat	is	that	provision-
al	 matrix	 proteins	 may	 affect	 cellular	
function	directly	and	thereby	modulate	
wound	repair	independent	of	GF	inter-
actions.	Such	may	be	the	case	with	FN,	
which	binds	VEGF	directly	and	IGF	and	
TGF-β	 indirectly	 (Macri et al.,	 2007),	
but	in	addition	has	a	pronounced	direct	
effect	on	cell	migration	during	embryo-
genesis	 (George et al.,	1993)	and	pre-
sumably	during	wound	repair	(Greiling	
and	Clark,	1997).
On	a	molecular	 level,	GF	 receptors	
co-localize	with	ECM	protein	receptors,	
i.e.,	integrins,	within	the	focal	contacts	
that	 form	 at	 the	 cell	membrane	when	
cells	bind	 to	ECM	proteins	 (Miyamoto 
et al.,	 1996;	 Plopper et al.,	 1995).	
Using	 magnetic	 microbeads	 coated	
with	FN	or	an	RGD-containing	peptide,	
Ingber’s	 group	 found	 that	 focal	 adhe-
sion	 complexes,	 which	 formed	 upon	
contact	 with	 microbeads,	 contained	
GF	 receptors	 as	 well	 as	 integrins	 and	
multiple	signaling	molecules,	including	
c-Src,	focal	adhesion	kinase,	phospha-
tidylinositol-3-kinase,	 phospholipase	
C-gamma,	 and	 Na+/H+	 antiporter	
(Plopper et al.,	 1995).	Yamada’s	 group	
demonstrated	that	EGF,	PDGF-BB,	and	
FGF-2	 produced	 a	 marked,	 transient	
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activation	 of	 extracellular	 signal-regu-
lated	 kinase,	 a	 signal-transduction	
molecule	 that	 induces	 mitogenesis,	
only	 if	 integrins	were	both	aggregated	
and	 occupied	 by	 FN	 or	 RGD-con-
taining	 peptide	 ligands	 (Miyamoto et 
al.,	 1996).	 These	 findings	 support	 the	
hypothesis	that	GFs	and	integrins	coop-
erate	 in	 a	 coordinate	 fashion	 to	 elicit	
signals	 necessary	 for	 cell	 function,	
especially	mitogenesis.	Because	signal-
transduction	 pathways	 are	 propagated	
along	nanoscale	scaffolding	complexes	
inside	the	cell,	coordinate	GF	and	ECM	
signals	from	the	external	milieu	appar-
ently	require	solid-state	presentation	in	
the	 same	 nanospace;	 otherwise	 their	
resultant	 signal	 transduction	 pathways	
would	be	unable	to	integrate.
Thus,	based	on	this	body	of	 in vitro	
and	 in vivo	 data,	GF–ECM	complexes	
may	 well	 be	 the	 most	 effective	 and	
efficient	method	 to	 stimulate	 cell	 pro-
liferation,	 as	 well	 as	 tissue	 healing	 or	
regeneration,	as	proposed	by	Upton	and	
colleagues	(2008).
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β-Papillomavirus Infection  
and Skin Cancer
Jan	Nico	Bouwes	Bavinck1,	Elsemieke	I.	Plasmeijer2	and		
Mariet	C.	W.	Feltkamp2
The development of highly sensitive PCr techniques and multiplex bead-based 
Luminex platforms has accelerated the search for a specific role of human papil-
loma viruses in the development of squamous cell carcinoma. Human papilloma-
viruses are most likely indirectly involved in this process by facilitating UV-related 
carcinogenesis via preventing UV-induced apoptosis or impairing DnA repair, but 
other mechanisms are also possible.
Journal of Investigative Dermatology (2008),	128,	1355–1358.	doi:10.1038/jid.2008.123
It	has	been	widely	accepted	that	human	
papillomavirus	 (HPV)	 16	 and	 related	
HPV	 types	 play	 a	 crucial	 role	 in	 the	
development	 of	 cervical	 and	 anogeni-
tal	carcinomas.	The	 role	of	HPV	 in	 the	
development	 of	 cutaneous	 squamous	
cell	 carcinoma	 (SCC)	 is	 still	 controver-
sial	(Asgari et al.,	2008,	this	issue).
The	 first	 time	 that	 HPV	 infection	
was	 linked	 with	 the	 development	 of	
skin	cancer	was	in	the	rare	genetic	dis-
ease	 epidermodysplasia	 verruciformis	
(EV).	EV	patients	develop	keratotic	skin	
lesions	 that	 display	 a	 high	 rate	 of	 pro-
gression	to	SCC,	mainly	on	sun-exposed	
skin.	They	also	exhibit	diminished	cell-	
mediated	 immunity	 and	 high	 suscepti-
bility	to	infection	with	β-papillomavirus	
(β-PV)	 types	 (formally	 called	 EV-HPV	
types;	Asgari et al.,	2008).
Organ-transplant	 recipients	 (OTRs)	
have	a	greatly	increased	risk	of	develop-
ing	warts	and	other	keratotic	skin	lesions,	
soon	 followed	 by	 the	 development	 of	
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